GenSight Biologics: Gene therapy: retinal & CNS degenerative pathologies and mitochondrial disease. Lead, GS010, Ph 3 for Leber Hereditary Optic Neuropathy (LHON). REVERSE Ph 3 topline data announced Apr 2018, RESCUE Ph 3 72-week data reported April 2019. Third Ph 3, REFLECT, exp 2020. Filing for MAA exp Q1 2020 in EU and Q4 2020 in US. Pipeline concomitant program, GS030: optogenetic combo drug + enhancing goggle device: non-syndromic retinitis pigmentosa. Optogenetic program and targeted disease immediately transferable to dry AMD. Platform combines mono-genetic therapy-based approach w core technology platform and proprietary Mitochondrial Targeting Sequence.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III
Disease Space
Ophthalmology
Industry
Biotechnology
Listing
Europe, Public
Market Cap
<100MM
Therapeutic Modalities
Gene Therapy
Website:
Address:
74, rue du Faubourg Saint-Antoine
Paris, 75012
France

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.